Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Poorly Differentiated Thyroid Gland Carcinoma”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Looking for participantsNCT06959641
What this trial is testing

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced Differentiated Thyroid Gland CarcinomaLocally Advanced Poorly Differentiated Thyroid Gland CarcinomaLocally Advanced Thyroid Gland Follicular Carcinoma+18 more
Northwestern University 33
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT03914300
What this trial is testing

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland Carcinoma+6 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Study completedNCT02244463
What this trial is testing

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerDifferentiated Thyroid Cancer
Dana-Farber Cancer Institute 46
Early research (Phase 1)Active Not RecruitingNCT04420754
What this trial is testing

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer
AffyImmune Therapeutics, Inc. 70
Early research (Phase 1)Study completedNCT04462471
What this trial is testing

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Who this might be right for
Thyroid CarcinomaThyroid CancerThyroid Cancer, Follicular+3 more
Memorial Sloan Kettering Cancer Center 8
Not applicableStudy completedNCT01534897
What this trial is testing

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Who this might be right for
Papillary Thyroid Carcinoma
Massachusetts General Hospital 10
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Study completedNCT00026533
What this trial is testing

Thalidomide in Treating Patients With Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Kenneth Ain
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544111
What this trial is testing

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, FollicularPapillary Thyroid Cancer+4 more
Memorial Sloan Kettering Cancer Center 19
Testing effectiveness (Phase 2)UnknownNCT02041260
What this trial is testing

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Who this might be right for
Differentiated Thyroid Cancer (DTC)Poorly Differentiated Thyroid Cancer
Thomas Jefferson University 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT02152995
What this trial is testing

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Who this might be right for
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+9 more
National Cancer Institute (NCI) 34